None of the proposed mechanisms of Alzheimer's disease (AD) fully explains the distribution
patterns of the neuropathological changes at the cellular and regional levels, and their …

Objective Detecting plasma tau biomarkers used to be impossible due to their low
concentrations in blood samples. Currently, new high-sensitivity assays made it a reality. We …

Abstract Alzheimer's disease (AD), a chronic neurodegenerative disease associated with the
loss of neurons in the brain, is the most pervasive type of dementia; 47 million people are …

Neurodegeneration currently remains without a differential diagnosis or cure. Tau protein is
one of the biomarkers of neurodegenerative diseases commonly known as tauopathies. Tau …

Beta amyloid peptide, tau, and phosphorylated tau are well recognized as promising
biomarkers for the diagnosis of Alzheimer's disease (AD). In this work, we developed a …

Visinin-like protein 1 (VILIP-1) recently emerged as a potential biomarker of Alzheimer's
disease (AD). This neuronal calcium sensor protein previously used as a marker of acute …

According to the World Alzheimer Report, in 2009 35.6 million people worldwide suffered
from dementia. Alzheimer disease (AD) is the major primary cause of dementia and affects …

Neuronal tau protein is one of the biomarkers of neurodegeneration which remains without a
cure and differential diagnosis. Hence, novel methods are needed for detection of tau …

The rapid increase in the older population has made age‐related diseases like Alzheimer's
disease (AD) a global concern. Given that there is still no cure for this neurodegenerative …

Aβ oligomers have been widely accepted as significant biomarkers for Alzheimer's disease
(AD) detection, monitoring, and therapy since they are highly correlated with AD …